FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Hikma Pharmaceuticals Ativan Injection Recall

Ativan Injection (lorazepam injection, USP), 2mg/mL, 1 mL vial, 25 vials per carton, R…

Hikma Pharmaceuticals USA Inc. · Cherry Hill, NJ

Risk level
Class II
Reported by FDA
Aug 17, 2022
Recall ID
D-1308-2022
Check your lot numberHow we source this data

Summary

Hikma Pharmaceuticals recalled Ativan Injection starting Jul 11, 2022. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1308-2022 on Aug 17, 2022. Reason: Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples. Status: Terminated.

Why it was recalled

Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.

Product description

Ativan Injection (lorazepam injection, USP), 2mg/mL, 1 mL vial, 25 vials per carton, RX Only, Manufactured by West-Ward Eatontown, NJ 07724, Carton NDC# 0641-6001-25, Vial NDC# 0641-6001-01

Lot numbers, UPCs & expiration codes

Lot # 060064Z, Exp. 06/2023

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1308-2022
Classification
Class II
Status
Terminated
Recall initiated
Jul 11, 2022
FDA report date
Aug 17, 2022
Quantity
301,400 vials
Recall type
Voluntary: Firm initiated
Recalling firm
Hikma Pharmaceuticals USA Inc.

Original FDA data

Every field from FDA enforcement report D-1308-2022, exactly as published.

Show all FDA fields
City
Cherry Hill
State
NJ
Status
Terminated
Country
United States
Event ID
90583
Address
2 Esterbrook Ln
Code information
Lot # 060064Z, Exp. 06/2023
Postal code
08003-4002
Report date
Aug 17, 2022
Product type
Drugs
Recall number
D-1308-2022
Classification
Class II
Recalling firm
Hikma Pharmaceuticals USA Inc.
Product quantity
301,400 vials
Termination date
Sep 14, 2023
Reason for recall
Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Ativan Injection (lorazepam injection, USP), 2mg/mL, 1 mL vial, 25 vials per carton, RX Only, Manufactured by West-Ward Eatontown, NJ 07724, Carton NDC# 0641-6001-25, Vial NDC# 0641-6001-01
Distribution pattern
Nationwide in the USA
Recall initiation date
Jul 11, 2022
Initial firm notification
Letter
Center classification date
Aug 5, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1308-2022, published Aug 17, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls